Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Niclo-Click PROTAC 5 is an experimental proteolysis-targeting chimera (PROTAC) designed to target the androgen receptor (AR) for degradation in the treatment of prostate cancer, particularly castration-resistant prostate cancer (CRPC). It is a hetero-bifunctional molecule consisting of niclosamide, which serves as the AR-binding ligand, and VHL-032, which acts as the ligand for the Von Hippel-Lindau (VHL) E3 ligase. These two components are connected via a linker synthesized using click chemistry. Although designed to initiate the ubiquitin-proteasome pathway for protein degradation, preclinical Western Blotting assays indicated that Niclo-Click PROTAC 5 does not effectively degrade the androgen receptor at concentrations up to 1 µM. Despite the lack of AR degradation, the compound exhibits selective antiproliferative activity against AR-positive prostate cancer cell lines such as LNCaP and 22Rv1, as well as the AR-negative PC-3 line, while failing to inhibit DU145 cells. This suggests that its mechanism for suppressing cancer cell proliferation is independent of the intended PROTAC-mediated AR degradation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Niclo-Click PROTAC 5.